CN1430514A - 加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途 - Google Patents

加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途 Download PDF

Info

Publication number
CN1430514A
CN1430514A CN01807334A CN01807334A CN1430514A CN 1430514 A CN1430514 A CN 1430514A CN 01807334 A CN01807334 A CN 01807334A CN 01807334 A CN01807334 A CN 01807334A CN 1430514 A CN1430514 A CN 1430514A
Authority
CN
China
Prior art keywords
dosage
days
galantamine
treatment
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01807334A
Other languages
English (en)
Chinese (zh)
Inventor
W·L·J·帕里斯
M·彭特科尔沃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1430514A publication Critical patent/CN1430514A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
CN01807334A 2000-04-03 2001-03-28 加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途 Pending CN1430514A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
US60/194,259 2000-04-03

Publications (1)

Publication Number Publication Date
CN1430514A true CN1430514A (zh) 2003-07-16

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01807334A Pending CN1430514A (zh) 2000-04-03 2001-03-28 加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途

Country Status (20)

Country Link
EP (1) EP1272192A2 (fr)
JP (1) JP2003528913A (fr)
KR (1) KR20020086911A (fr)
CN (1) CN1430514A (fr)
AU (2) AU2001265844B2 (fr)
BG (1) BG107093A (fr)
BR (1) BR0109770A (fr)
CA (1) CA2310926C (fr)
CZ (1) CZ20023543A3 (fr)
EE (1) EE200200554A (fr)
HR (1) HRP20020778A2 (fr)
HU (1) HUP0300566A3 (fr)
IL (1) IL152061A0 (fr)
MX (1) MXPA02009777A (fr)
NO (1) NO20024746L (fr)
PL (1) PL361272A1 (fr)
RU (1) RU2002129298A (fr)
SK (1) SK15422002A3 (fr)
WO (1) WO2001074339A2 (fr)
ZA (1) ZA200207935B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228638A (zh) * 2013-03-07 2016-01-06 贝尔毕贝希尔私人有限公司 富含加兰他敏的凤蝶朱顶红的提取物
CN107847504A (zh) * 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 淀粉状蛋白β的加兰他敏清除
WO2023036105A1 (fr) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 Méthode de traitement d'une maladie neurodégénérative

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
ES2293287T3 (es) 2003-07-25 2008-03-16 F. Hoffmann-La Roche Ag Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
AU2009229372C1 (en) 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2013160728A1 (fr) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Composés à double ciblage pour le traitement de la maladie d'alzheimer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en) * 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310950C (fr) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. Posologie de galantamine efficace qui reduit les effets secondaires
CA2310990A1 (fr) * 2000-04-03 2000-10-09 Michael Pontecorvo Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228638A (zh) * 2013-03-07 2016-01-06 贝尔毕贝希尔私人有限公司 富含加兰他敏的凤蝶朱顶红的提取物
CN107847504A (zh) * 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 淀粉状蛋白β的加兰他敏清除
WO2023036105A1 (fr) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 Méthode de traitement d'une maladie neurodégénérative

Also Published As

Publication number Publication date
RU2002129298A (ru) 2004-03-27
KR20020086911A (ko) 2002-11-20
HUP0300566A2 (hu) 2003-06-28
BG107093A (bg) 2003-06-30
PL361272A1 (en) 2004-10-04
AU6584401A (en) 2001-10-15
WO2001074339A3 (fr) 2002-09-12
HUP0300566A3 (en) 2004-10-28
WO2001074339A2 (fr) 2001-10-11
NO20024746D0 (no) 2002-10-02
NO20024746L (no) 2002-11-28
CA2310926A1 (fr) 2000-10-04
AU2001265844B2 (en) 2005-04-14
SK15422002A3 (sk) 2003-04-01
CZ20023543A3 (cs) 2003-03-12
BR0109770A (pt) 2003-02-04
ZA200207935B (en) 2004-01-30
EE200200554A (et) 2004-04-15
MXPA02009777A (es) 2003-03-27
HRP20020778A2 (en) 2004-04-30
EP1272192A2 (fr) 2003-01-08
IL152061A0 (en) 2003-05-29
JP2003528913A (ja) 2003-09-30
CA2310926C (fr) 2002-10-15

Similar Documents

Publication Publication Date Title
Cook Jr et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation
CN1084618C (zh) 5－羟色胺拮抗剂的新应用
Johnson et al. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing
Heinrich et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial
JP2021119186A (ja) 機能低下を治療するためのプリドピジンの使用
Izumi et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression
AU2010213663A1 (en) Compositions and methods for extended therapy with aminopyridines
Matsuda et al. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy
Harvey et al. Blonanserin versus haloperidol in Japanese patients with schizophrenia: a phase 3, 8‐week, double‐blind, multicenter, randomized controlled study
Dardin et al. The effects of resistance training in patients with primary Sjogren’s syndrome
CN1430514A (zh) 加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途
Yan et al. Mercury poisoning presenting with hypertension: report of 2 cases
US20230000799A1 (en) Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
Larone et al. Exserohilum rostratum: anatomy of a national outbreak of fungal meningitis
Paul et al. Brunner & Suddarth's textbook of Canadian medical-surgical nursing
Cahaya et al. Incidence of Orthostatic Hypotension in Schizophrenic Patients Using Antipsychotics at Sambang Lihum Mental Health Hospital, South Kalimantan
Matsumoto et al. Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women
AU2001265844A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
WO2023233570A1 (fr) Composition de gouttes nasales
WO2005105089A1 (fr) Remède pour maladies psycho névrotiques
WO2023215277A1 (fr) Triméprazine destiné à être utilisé dans le traitement de la névralgie du trijumeau et pour réduire la douleur associée à celle-ci
Zagami et al. Myasthenia gravis symptom response to huperzine A, pyridostigmine bromide, and an immunomodulatory incorporated regimen: A multi-case study
Aakhus et al. Single session educational programme for caregivers of psychogeriatric in‐patients–results from a randomised controlled pilot study
Sirven et al. Marijuana as a treatment for epilepsy and multiple sclerosis?: A “grass roots” movement
HK1055402A (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1055402

Country of ref document: HK